Employing the overexpression of the same set of genes and loss of p53 function in a mouse model of ovarian cancers treated with immunotherapy resulted in similar heterogeneous responses to checkpoint therapy and the beginnings of experimental tests of genes and products that could modify the results of the responses to cancer therapies14. Here, TP53 is linked to ovarian cancer.